Opportunity Information: Apply for RFA HG 22 009
This NIH funding opportunity (RFA-HG-22-009) supports the creation of one or more Omics Production Centers (OPCs) under a U01 cooperative agreement mechanism, with clinical trials not allowed. The program sits inside a larger, tightly coordinated consortium focused on pushing multi-omics approaches forward for studying health and disease in diverse populations. In practical terms, the OPCs are meant to function as high-capacity, high-throughput laboratory hubs that can reliably generate large volumes of high-quality omics data from human biospecimens, while also helping the broader consortium agree on how those data should be produced, standardized, integrated, and shared for maximum scientific value.
The core purpose is not to run a traditional disease-discovery project aimed at proving one specific biological hypothesis. Instead, the emphasis is on validating, refining, and generalizing multi-omic methods and workflows so they can be applied across diseases, settings, and populations. The consortium will intentionally work in clinical contexts where multi-omics is expected to be especially informative, then combine molecular measurements with rich phenotypic information and environmental exposure data, including social determinants of health (SDOH). The overarching idea is to see how well integrated multi-omic profiles can characterize healthy versus disease states, and to determine what technical, analytical, and operational practices are needed for these approaches to be reliable, comparable, and broadly useful.
Within the consortium structure, the OPCs partner directly with Disease Study Sites (DSS; RFA-HG-22-008), which are responsible for clinical recruitment and biosample collection, and with a Data Analysis and Coordination Center (DACC; RFA-HG-22-010), which supports harmonization, integration, analysis coordination, and data sharing. The OPCs primary job is to take the biosamples provided by the DSS and generate omics datasets using high-throughput molecular assays. While the FOA does not list every assay type in the excerpt provided, the intent of an "omics production" center in this context typically covers scalable molecular profiling workflows that may span multiple modalities (for example, genomic, transcriptomic, epigenomic, proteomic, metabolomic, or related platforms), so long as the outputs can be standardized and integrated across sites and conditions.
Beyond raw data generation, the OPCs are expected to be active consortium partners rather than fee-for-service labs. That means contributing to consortium-wide protocol development (how samples are processed, how assays are run, what quality control thresholds apply, what metadata must accompany each dataset), supporting the development of harmonization and integration strategies, and participating in methods development and best-practices work that will help the field apply multi-omics consistently. A major deliverable for the entire initiative is a multi-dimensional, community-available dataset, meaning the program is explicitly designed to create a resource that other researchers can use after appropriate sharing processes. The production centers role is central to making that dataset coherent, comparable, and technically trustworthy across different study sites and populations.
The funding opportunity is categorized as discretionary and uses a cooperative agreement instrument, which typically implies substantial NIH involvement in governance, coordination, and milestone-based collaboration. The agency is the National Institutes of Health, and the activity aligns with health-related research infrastructure and methods advancement. The opportunity lists multiple CFDA numbers (93.113, 93.172, 93.396, 93.399), indicating participation or alignment across relevant NIH programs and institutes. The original closing date shown is November 18, 2022, and the award ceiling is listed as $2,700,000, with the expected number of awards not specified in the provided text.
A wide range of applicants are eligible, including state, county, and local governments; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities; nonprofits (both 501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly calls out eligibility for several mission-driven institution types and community-centered organizations, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations and regional organizations. In terms of foreign involvement, non-domestic (non-U.S.) entities and non-U.S. components of U.S. organizations are not eligible to apply as applicants, but foreign components are allowed as defined under the NIH Grants Policy Statement, meaning portions of the work can involve foreign collaborators under NIH rules even though the applicant organization must be domestic.
Taken together, this FOA is essentially building the laboratory production backbone of a national multi-site effort: generate high-quality, high-throughput multi-omics data from shared biosamples; help define and enforce standards so results are comparable; work with coordinating and analysis partners to integrate omics with phenotype, exposure, and SDOH data; and ultimately deliver a well-documented, multi-dimensional dataset and a set of transferable methods and best practices that improve how multi-omics is applied to questions of health and disease across diverse populations.Apply for RFA HG 22 009
- The National Institutes of Health in the education, environment, health sector is offering a public funding opportunity titled "Multi-Omics for Health and Disease - 'Omics Production Centers (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113, 93.172, 93.396, 93.399.
- This funding opportunity was created on 2022-09-07.
- Applicants must submit their applications by 2022-11-18. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $2,700,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs) - NIH RFA-HG-22-009: Omics Production Centers (OPCs)
What is the NIH opportunity RFA-HG-22-009 funding?
This funding opportunity supports the creation of one or more Omics Production Centers (OPCs). These centers are intended to operate as high-capacity, high-throughput laboratory hubs that generate large volumes of high-quality omics data from human biospecimens, while also helping the broader consortium align on standardized ways to produce, integrate, and share those data.
What funding mechanism is used for this program?
The program uses a U01 cooperative agreement mechanism. This typically involves substantial NIH involvement in coordination, governance, and milestone-driven collaboration across the participating sites.
Are clinical trials allowed under this opportunity?
No. Clinical trials are not allowed under this funding opportunity.
What is the main purpose of an Omics Production Center (OPC) in this initiative?
The OPCs are primarily responsible for taking biospecimens provided by clinical study partners and generating omics datasets using scalable, high-throughput molecular assays. In addition to producing data, OPCs are expected to help define and implement shared standards, protocols, quality controls, and metadata practices so data are comparable across sites and populations.
Is this program focused on testing a single disease hypothesis?
No. The emphasis is not on a traditional, single-hypothesis disease-discovery project. Instead, the program focuses on validating, refining, and generalizing multi-omics methods and workflows so they can be reliably applied across diseases, settings, and diverse populations.
How does this opportunity fit into a larger consortium?
The OPCs are part of a tightly coordinated consortium designed to advance multi-omics approaches for studying health and disease in diverse populations. The consortium structure intentionally supports common standards, harmonized workflows, and coordinated data integration and sharing.
Who are the key partners OPCs work with in the consortium?
OPCs partner directly with Disease Study Sites (DSS; RFA-HG-22-008) and a Data Analysis and Coordination Center (DACC; RFA-HG-22-010). DSS are responsible for clinical recruitment and biosample collection, while the DACC supports harmonization, integration, analysis coordination, and data sharing across the consortium.
What do Disease Study Sites (DSS) do versus what OPCs do?
DSS handle clinical recruitment and biosample collection. OPCs receive those biosamples and generate the omics datasets using high-throughput assays, while also contributing to consortium-wide standards and best practices.
What does the Data Analysis and Coordination Center (DACC) do in relation to OPCs?
The DACC supports harmonization, integration, analysis coordination, and data sharing. OPCs contribute by producing standardized, high-quality omics datasets and participating in the consortium processes that make those data easier to integrate and analyze across sites.
What kinds of omics data are expected to be produced?
The excerpt does not enumerate every assay type. However, the intent of an "omics production" center in this context is to support scalable molecular profiling workflows across multiple modalities (for example, genomic, transcriptomic, epigenomic, proteomic, metabolomic, or related platforms), as long as outputs can be standardized and integrated across sites and conditions.
What makes the OPC role different from a fee-for-service core lab?
OPCs are expected to be active consortium partners, not just service providers. This includes contributing to protocol development, agreeing on quality control thresholds, defining required metadata, supporting harmonization/integration strategies, and participating in methods development and best-practices work.
What types of standards and protocols are OPCs expected to help develop?
OPCs are expected to contribute to consortium-wide decisions and documentation about sample processing, assay execution, quality control thresholds, and the metadata that must accompany each dataset, with the goal of ensuring results are comparable and technically reliable across sites.
How are multi-omics data expected to be used in this program?
The consortium will apply multi-omics in clinical contexts where these approaches are expected to be particularly informative. The program will combine molecular measurements with rich phenotypic information and environmental exposure data, including social determinants of health (SDOH), to evaluate how well integrated profiles characterize healthy versus disease states and what practices are needed for reliability and comparability.
Does the program include environmental exposure and social determinants of health (SDOH) data?
Yes. The initiative is designed to integrate molecular measurements with rich phenotype and environmental exposure information, explicitly including SDOH, to support more complete characterization of health and disease across diverse populations.
What is a major deliverable of the overall initiative?
A major deliverable is a multi-dimensional, community-available dataset. The program is explicitly structured to create a resource that other researchers can use after appropriate data sharing processes.
What is the OPC contribution to making the dataset useful to the broader community?
OPCs play a central role in ensuring the omics data are high-quality, coherent, comparable, and well-documented across study sites and populations, supporting standards, quality controls, and associated metadata practices that enable downstream integration and re-use.
Which agency sponsors this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
What is the award ceiling listed for this opportunity?
The award ceiling listed in the provided information is $2,700,000.
How many awards will NIH make under this FOA?
The expected number of awards is not specified in the provided information.
What is the closing date shown for this opportunity?
The original closing date shown is November 18, 2022.
What CFDA numbers are associated with this opportunity?
The opportunity lists multiple CFDA numbers: 93.113, 93.172, 93.396, and 93.399.
Who is eligible to apply?
A wide range of applicants are eligible, including state, county, and local governments; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities; nonprofits (501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses); and small businesses.
Are small businesses eligible to apply?
Yes. Small businesses are included in the eligible applicant types listed in the provided information.
Are for-profit organizations eligible to apply?
Yes. For-profit organizations (other than small businesses) are listed as eligible, and small businesses are also listed as eligible separately.
Are institutions that serve specific communities explicitly encouraged or eligible?
Yes. The FOA explicitly calls out eligibility for mission-driven and community-centered institution types and organizations, including HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations and regional organizations.
Are non-U.S. (foreign) organizations eligible to apply as the main applicant?
No. Non-domestic (non-U.S.) entities and non-U.S. components of U.S. organizations are not eligible to apply as applicants under this opportunity.
Can a project include foreign collaborators or foreign components?
Yes. Foreign components are allowed as defined under the NIH Grants Policy Statement, meaning portions of the work can involve foreign collaborators under NIH rules even though the applicant organization must be domestic.
What does "discretionary" mean in the context of this opportunity?
The opportunity is categorized as discretionary, indicating it is a federal assistance program where awards are made based on eligibility and competitive review rather than by formula entitlement.
What is the overall vision of the initiative this OPC program supports?
The initiative is building the laboratory production backbone for a national multi-site effort: generate high-quality, high-throughput multi-omics data from shared biospecimens; define and enforce standards so results are comparable; coordinate with analysis and data-sharing partners to integrate omics with phenotype, exposure, and SDOH data; and deliver a community-available dataset plus transferable methods and best practices for applying multi-omics to health and disease across diverse populations.
Browse more opportunities from the same category: Education, Environment, Health
Next opportunity: Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
Previous opportunity: Bureau of Land Management Arizona Wildlife Resource Management
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HG 22 009
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HG 22 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional) Apply for RFA OD 22 028 Funding Number: RFA OD 22 028 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: $350,000 |
| Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R01 Clinical Trial Optional) Apply for PAR 23 042 Funding Number: PAR 23 042 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| Genomic Community Resources (U24 Clinical Trial Not Allowed) Apply for PAR 23 085 Funding Number: PAR 23 085 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| Biomedical Data Repository (U24 - Clinical Trials Not Allowed) Apply for PAR 23 079 Funding Number: PAR 23 079 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| Biomedical Knowledgebase (U24 - Clinical Trials Not Allowed) Apply for PAR 23 078 Funding Number: PAR 23 078 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) Apply for RFA ES 23 004 Funding Number: RFA ES 23 004 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| NIH Medical Scientist Partnership Program (FM1 Clinical Trial Not Allowed) Apply for PAR 23 109 Funding Number: PAR 23 109 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed) Apply for PAR 23 139 Funding Number: PAR 23 139 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: $275,000 |
| Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional) Apply for RFA ES 23 001 Funding Number: RFA ES 23 001 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: $2,000,000 |
| STrengthening Research Opportunities for NIH Grants (STRONG): Structured Institutional Needs Assessment and Action Plan Development for Resource Limited Institutions (RLIs) (UC2 - Clinical Trial Not Allowed) Apply for PAR 23 144 Funding Number: PAR 23 144 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: $250,000 |
| Tobacco Regulatory Science (R01 Clinical Trial Optional) Apply for RFA OD 23 017 Funding Number: RFA OD 23 017 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: $500,000 |
| Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed) Apply for PAR 23 184 Funding Number: PAR 23 184 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) Apply for RFA ES 23 011 Funding Number: RFA ES 23 011 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: $275,000 |
| NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Trial Not Allowed) Apply for PAR 23 229 Funding Number: PAR 23 229 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33) Apply for PA 23 263 Funding Number: PA 23 263 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| Enhancement and Management of Established Biomedical Data Repositories and Knowledgebases (U24 Clinical Trial Not Allowed) Apply for PAR 23 237 Funding Number: PAR 23 237 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| Early-stage Biomedical Data Repositories and Knowledgebases (R24 Clinical Trial Not Allowed) Apply for PAR 23 236 Funding Number: PAR 23 236 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: $350,000 |
| Intervention Research to Improve Native American Health (R21 Clinical Trials Optional) Apply for PAR 23 299 Funding Number: PAR 23 299 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| Intervention Research to Improve Native American Health (R34 Clinical Trial Optional) Apply for PAR 23 285 Funding Number: PAR 23 285 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
| Center for Exposome Research Coordination to Accelerate Precision Environmental Health (U24 Clinical Trial Not Allowed) Apply for RFA ES 23 010 Funding Number: RFA ES 23 010 Agency: National Institutes of Health Category: Education, Environment, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HG 22 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.